Am­gen scores pos­i­tive PhI­II car­dio out­comes for its PC­SK9 fran­chise drug Repatha

Am­gen got an­oth­er round of good news for its PC­SK9 fran­chise drug Repatha. Hot on the heels of a ma­jor patent fight vic­to­ry over Sanofi and Re­gen­eron, the big phar­ma com­pa­ny says in­ves­ti­ga­tors gar­nered pos­i­tive top-line car­dio out­comes da­ta from their crit­i­cal FOURI­ER tri­al.

There’s no da­ta avail­able yet, but the com­pa­ny re­ports that Repatha proved to sig­nif­i­cant­ly re­duce the risk of car­dio events in pa­tients with clin­i­cal­ly ev­i­dent ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease. The drug al­so hit on an end­point for cog­ni­tive func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER